Developmental Pharmacology Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Developmental Pharmacology. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Developmental Pharmacology Indian Medical PG Question 1: Which of the following statements about hypolipidemic drugs is false?
- A. Gemfibrozil causes myopathy
- B. Gemfibrozil can increase myopathy caused by statins
- C. Lovastatin can cause hepatic dysfunction
- D. Cholesterol reducing drugs are contraindicated in child less than 8 years (Correct Answer)
Developmental Pharmacology Explanation: ***Cholesterol reducing drugs are contraindicated in child less than 8 years***
- While cholesterol-lowering drugs are generally avoided in young children, there are specific **genetic dyslipidemias** where treatment may be initiated earlier under specialist supervision [1].
- The statement is **false** because some genetic conditions may necessitate earlier treatment, making a blanket contraindication for all children under 8 inaccurate [1].
*Gemfibrozil causes myopathy*
- **Gemfibrozil** (a fibric acid derivative) can indeed cause **myopathy**, especially when used alone or in combination with other lipid-lowering agents [2].
- This adverse effect is thought to be due to its mechanism of action affecting fatty acid metabolism and muscle integrity.
*Gemfibrozil can increase myopathy caused by statins*
- The co-administration of **gemfibrozil** with **statins** significantly increases the risk of **myopathy** and **rhabdomyolysis** [2].
- This is primarily due to gemfibrozil inhibiting the **glucuronidation** of statins, which increases statin plasma concentrations [2].
*Lovastatin can cause hepatic dysfunction*
- **Statins**, including **lovastatin**, can cause **elevations in liver transaminases** and, in rare cases, lead to **drug-induced liver injury** [1].
- Regular monitoring of liver function tests is recommended when initiating statin therapy and during follow-up [2].
Developmental Pharmacology Indian Medical PG Question 2: What is the mechanism of metabolism for alcohol, aspirin, and phenytoin at high doses?
- A. First pass kinetics
- B. First order kinetics
- C. Zero order kinetics (Correct Answer)
- D. Second order kinetics
Developmental Pharmacology Explanation: ***Zero order kinetics***
- This mechanism occurs when the **metabolic enzymes become saturated at high drug concentrations**, leading to a constant amount (not a constant percentage) of drug being eliminated per unit time.
- Alcohol, aspirin, and phenytoin are examples of drugs that exhibit **saturable metabolism**, transitioning from first-order to zero-order kinetics at higher doses.
*First pass kinetics*
- This describes the **metabolism of a drug by the liver or gut wall enzymes before it reaches systemic circulation** after oral administration.
- While relevant to the oral bioavailability of these drugs, it does not describe the specific mechanism of elimination at high doses.
*First order kinetics*
- In this mechanism, a **constant fraction or percentage of the drug is eliminated per unit of time**, meaning the rate of elimination is directly proportional to the drug concentration.
- Most drugs follow first-order kinetics at therapeutic doses because metabolizing enzymes are not saturated.
*Second order kinetics*
- This is a **less common pharmacokinetic model** where the rate of elimination is proportional to the square of the drug concentration or involves two reactants.
- It does not typically describe the common elimination patterns of most drugs, including alcohol, aspirin, and phenytoin.
Developmental Pharmacology Indian Medical PG Question 3: Which of the following is the most appropriate initial antihypertensive treatment for an elderly patient with isolated systolic hypertension?
- A. Amlodipine (Correct Answer)
- B. Lisinopril
- C. Atenolol
- D. Losartan
Developmental Pharmacology Explanation: Amlodipine
- **Calcium channel blockers (CCBs)**, especially dihydropyridines like amlodipine, are recommended as initial therapy for isolated systolic hypertension in the elderly due to their effectiveness in reducing elevated systolic pressure [2].
- They are well-tolerated and can reduce the risk of cardiovascular events in this population.
*Lisinopril*
- **ACE inhibitors** like lisinopril are effective antihypertensives but are generally not the first-line choice for isolated systolic hypertension, particularly in elderly patients where a decrease in diastolic pressure might be detrimental [1].
- They are associated with side effects such as **cough** and can cause **acute kidney injury**, which can be a concern in older adults [1].
Atenolol
- **Beta-blockers** like atenolol are generally not recommended as first-line therapy for isolated systolic hypertension due to their limited efficacy in lowering systolic blood pressure compared to other drug classes.
- They may also worsen certain conditions common in the elderly, such as **peripheral vascular disease** and **bronchospastic lung disease**.
*Losartan*
- **Angiotensin receptor blockers (ARBs)** like losartan are effective for hypertension but are not typically favored over CCBs or thiazide diuretics as initial monotherapy for isolated systolic hypertension in the elderly [1].
- They share similar side effects and contraindications with ACE inhibitors, including the risk of **renal dysfunction** [1].
Developmental Pharmacology Indian Medical PG Question 4: A term infant is born to a known HIV-positive mother. She has been taking antiretroviral medications for the weeks prior to the delivery of her infant. Routine management of the healthy infant should include which of the following?
- A. HIV ELISA on the infant to determine if congenital infection has occurred
- B. Admission to the neonatal intensive care unit for close cardiovascular monitoring
- C. Chest radiographs to evaluate for congenital Pneumocystis carinii
- D. A course of zidovudine for the infant (Correct Answer)
Developmental Pharmacology Explanation: ***A course of zidovudine for the infant***
- This is the standard of care for newborns exposed to HIV prenatally, even if the mother received **antiretroviral therapy (ART)**.
- **Zidovudine (AZT)** prophylaxis significantly reduces the risk of **perinatal HIV transmission**.
*HIV ELISA on the infant to determine if congenital infection has occurred*
- **HIV ELISA** tests detect **maternal antibodies** passed to the infant, which can persist for up to 18 months, leading to **false positive results**.
- **HIV DNA PCR** or **RNA assays** are used to diagnose HIV infection in infants.
*Admission to the neonatal intensive care unit for close cardiovascular monitoring*
- Admission to the **NICU** is generally reserved for **premature** or **symptomatic infants**, or those with specific complications.
- A **healthy, term infant** born to an HIV-positive mother on ART does not routinely require NICU admission.
*Chest radiographs to evaluate for congenital Pneumocystis carinii*
- **Pneumocystis jirovecii pneumonia (PJP)** typically presents in HIV-infected infants between **3 to 6 months of age**, not at birth.
- Prophylaxis with **trimethoprim-sulfamethoxazole (TMP-SMX)** is initiated at 4-6 weeks of age for HIV-exposed infants.
Developmental Pharmacology Indian Medical PG Question 5: Which sedative is most appropriate in a patient with hepatic impairment?
- A. Midazolam
- B. Lorazepam (Correct Answer)
- C. Zolpidem
- D. Diazepam
Developmental Pharmacology Explanation: ***Lorazepam***
- **Lorazepam** is primarily metabolized by **glucuronidation**, a phase II metabolic pathway that is relatively preserved in most forms of hepatic impairment
- This makes it a safer choice in patients with **liver disease** compared to other benzodiazepines that rely heavily on oxidative metabolism
- Preferred sedative in cirrhosis and acute liver failure
*Midazolam*
- **Midazolam** is primarily metabolized by the **cytochrome P450 3A4 (CYP3A4)** enzyme system in the liver
- Hepatic impairment can significantly reduce **CYP3A4 activity**, leading to prolonged half-life, increased sedative effects, and accumulation of the drug
- Should be avoided or dose-reduced in hepatic impairment
*Zolpidem*
- **Zolpidem** is extensively metabolized by **hepatic cytochrome P450 enzymes**, particularly CYP3A4 and CYP2C9
- In patients with **hepatic impairment**, its clearance is significantly reduced, necessitating dose reduction to avoid excessive sedation and adverse effects
- Maximum dose should be limited to 5 mg in hepatic dysfunction
*Diazepam*
- **Diazepam** undergoes extensive **hepatic oxidative metabolism** via CYP2C19 and CYP3A4 to active metabolites such as **desmethyldiazepam**, which also have long half-lives
- In patients with **liver disease**, this metabolism is impaired, leading to prolonged drug action, increased sedation, and accumulation of the parent drug and active metabolites
- Active metabolites can accumulate for days to weeks in hepatic impairment
Developmental Pharmacology Indian Medical PG Question 6: For the treatment of kala-azar, the daily dose of miltefosine in a 3-year-old child who weighs 15 kg is
- A. 20 mg
- B. 40 mg (Correct Answer)
- C. 10 mg
- D. 30 mg
Developmental Pharmacology Explanation: ***40 mg***
- Miltefosine dosage for children weighing 12 to 29 kg (including a 15 kg child) is typically **2.5 mg/kg body weight per day orally**.
- For a 15 kg child, this translates to 2.5 mg/kg * 15 kg = **37.5 mg**, which is rounded to **40 mg** for practical dosing since miltefosine capsules come in 10 mg or 50 mg sizes.
*20 mg*
- This dose is lower than the recommended **2.5 mg/kg/day** for a 15 kg child, which would be 37.5 mg.
- An underdose of miltefosine could lead to **treatment failure** and the development of drug resistance.
*10 mg*
- This dose is significantly lower than the recommended therapeutic dose for a 15 kg child, which requires approximately **37.5 mg daily**.
- Such a low dose would be **ineffective** in treating kala-azar, risking worsening disease.
*30 mg*
- While closer than 10 mg or 20 mg, 30 mg is still below the calculated **37.5 mg/day** for a 15 kg child.
- An insufficient dose may compromise the efficacy of treatment and lead to **suboptimal parasitic clearance**.
Developmental Pharmacology Indian Medical PG Question 7: What is the treatment of choice for a 5-year-old child with bedwetting?
- A. No treatment
- B. Motivational therapy (Correct Answer)
- C. Imipramine
- D. Desmopressin
Developmental Pharmacology Explanation: ***Motivational therapy***
- This is the **first-line active treatment** for **primary nocturnal enuresis** in children, involving encouragement, positive reinforcement (star charts), rewards, and education about bladder control.
- It focuses on **behavioral strategies** and can be highly effective with parental involvement.
- When intervention is pursued at age 5, motivational therapy is preferred over pharmacological options due to safety and effectiveness.
*No treatment*
- At age 5, **watchful waiting with reassurance** is often appropriate since nocturnal enuresis is common at this age (affects 15-20% of 5-year-olds) and has a **spontaneous resolution rate of 15% per year**.
- However, when the question asks for "treatment of choice," it implies active intervention rather than observation alone.
- Active behavioral therapy is preferred when bedwetting causes distress or affects the child's self-esteem.
*Imipramine*
- **Imipramine** is a **tricyclic antidepressant** with anticholinergic effects that can reduce bladder contractions, but it has significant side effects including **cardiac arrhythmias** and is **not first-line treatment**.
- It is typically reserved for children ≥7 years after behavioral interventions fail, due to its potential adverse effects and high relapse rate after discontinuation.
*Desmopressin*
- **Desmopressin** is an **antidiuretic hormone analog** that reduces urine production overnight.
- While effective, it is typically reserved for children ≥6 years who are unresponsive to behavioral therapy or for **short-term situational use** (e.g., sleepovers, camps).
- Side effects include potential **hyponatremia** and high relapse rate after discontinuation.
Developmental Pharmacology Indian Medical PG Question 8: Which of the following is true regarding the treatment of cocaine withdrawal symptoms?
- A. Fluoxetine
- B. Antidepressants
- C. No specific drug (Correct Answer)
- D. Benzodiazepines
Developmental Pharmacology Explanation: ***No specific drug***
- Currently, there is **no FDA-approved pharmacotherapy** for the treatment of cocaine withdrawal symptoms or for preventing relapse in cocaine dependence.
- Management primarily focuses on **supportive care**, **psychotherapy** (cognitive behavioral therapy, contingency management), and addressing **co-occurring mental health disorders**.
- Unlike alcohol or opioid withdrawal, cocaine withdrawal is not life-threatening and does not require specific medication.
*Fluoxetine*
- Fluoxetine is a **selective serotonin reuptake inhibitor (SSRI)** primarily used to treat depression and anxiety disorders.
- While depression can be a symptom of cocaine withdrawal, fluoxetine has **not been shown to be effective** for reducing cocaine use or treating cocaine withdrawal specifically.
- Multiple clinical trials have failed to demonstrate benefit for cocaine dependence treatment.
*Antidepressants*
- While various antidepressants (including desipramine, bupropion) have been investigated, there is **no strong evidence** to support their routine use as primary treatment for cocaine withdrawal or dependence.
- Their effectiveness in this context is **limited and inconsistent** across studies.
- They may be used to treat **co-occurring depressive disorders** but not as primary cocaine withdrawal treatment.
*Benzodiazepines*
- Benzodiazepines are primarily used to manage **acute anxiety and seizures** during withdrawal from GABAergic substances like **alcohol and sedatives**.
- They are generally **not recommended** for cocaine withdrawal as cocaine withdrawal does not cause seizures or dangerous autonomic instability.
- May be used only for **severe agitation** or **co-occurring alcohol withdrawal**, but carry their own dependence potential and do not address cocaine withdrawal itself.
Developmental Pharmacology Indian Medical PG Question 9: A G2 P1 - 29-year-old female delivered a baby, but the baby died within 48 hours due to medical reasons. What drug will you advise to stop breast milk secretion?
- A. None of the options
- B. Ergot alkaloids
- C. Cabergoline (Correct Answer)
- D. Both B & C
Developmental Pharmacology Explanation: ***Cabergoline***
- **Cabergoline** is a **non-ergot dopamine agonist** that effectively inhibits pituitary prolactin secretion, leading to the suppression of lactation.
- It works by acting on **D2 dopamine receptors** in the pituitary gland, thereby preventing milk secretion after delivery.
- It is the **preferred first-line agent** for lactation suppression due to its superior efficacy, better tolerability, longer half-life (allowing single or twice-daily dosing over 2 days), and lower side effect profile.
*None of the options*
- This option is incorrect because there are specific pharmacological agents available and recommended for **lactation suppression** in such circumstances.
- **Cabergoline** is a well-established and commonly used drug for this purpose.
*Ergot alkaloids*
- While **bromocriptine** (an ergot-derived dopamine agonist) was historically used for lactation suppression, it is no longer preferred.
- **Cabergoline** has largely replaced bromocriptine due to better tolerability, longer half-life, less frequent dosing, and fewer side effects (bromocriptine causes more nausea, vomiting, and orthostatic hypotension).
- Note: **Cabergoline itself is a non-ergot dopamine agonist**, making it pharmacologically distinct from ergot alkaloids.
*Both B & C*
- This option is incorrect because **cabergoline is not an ergot alkaloid**—it is a non-ergot dopamine agonist.
- While bromocriptine (an ergot derivative) can suppress lactation, **cabergoline alone** is the preferred choice with superior efficacy and safety profile.
- Combining or equating these agents is not standard clinical practice.
Developmental Pharmacology Indian Medical PG Question 10: Drug X has an affinity for albumin, while drug Y has 150 times greater affinity. Which of the following statements is MOST accurate?
- A. Drug X will be more available in tissues
- B. Drug Y will be less available in tissues
- C. Toxicity of drug Y may be influenced by multiple factors, not just its binding.
- D. The free concentration of drug X in blood is higher, facilitating tissue distribution. (Correct Answer)
Developmental Pharmacology Explanation: ***Correct: The free concentration of drug X in blood is higher, facilitating tissue distribution.***
- This is the **MOST accurate and complete** answer because it directly addresses the pharmacokinetic mechanism
- Drug X has **lower affinity for albumin** → larger proportion remains **unbound (free)** in plasma
- Only **free (unbound) drug** can cross capillary membranes to distribute into tissues
- This statement precisely explains both the **cause** (higher free concentration) and **effect** (facilitating tissue distribution)
*Drug X will be more available in tissues*
- This statement is **factually true** and follows logically from drug X's lower protein binding
- However, it's **less precise** than the correct answer because it doesn't explicitly explain the **mechanism** (higher free concentration)
- The term "available" is less specific than "free concentration," which is the key pharmacokinetic parameter
*Drug Y will be less available in tissues*
- This statement is also **factually true** - drug Y's **150× higher albumin affinity** means more drug is bound
- Higher protein binding → **smaller free fraction** → less tissue distribution
- However, like option 1, this doesn't explicitly state the **mechanistic principle** involving free drug concentration
- The question asks for the MOST accurate statement, and this focuses on drug Y rather than explaining the core concept
*Toxicity of drug Y may be influenced by multiple factors, not just its binding*
- While this is a **true general principle**, it's **not directly relevant** to the specific question
- This statement doesn't address the **pharmacokinetic implications** of differential albumin binding
- It's too vague and doesn't demonstrate understanding of the relationship between protein binding and tissue distribution
- The question specifically asks about the affinity differences and their consequences
More Developmental Pharmacology Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
